Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health Services Inc. has demonstrated robust performance, particularly within its OP Rehab segment, which is growing in the double digits and maintaining attractive margins. The Pharmacy Solutions segment reported a 43% year-over-year increase in specialty revenue, reaching approximately $2.6 billion in 2025, with management projecting further margin improvements and substantial EBITDA growth driven by strategic M&A. Additionally, the Provider division is benefiting from stable reimbursement rates and increased demand, evidenced by a 15% year-over-year growth in home health average daily census in 4Q:25, further enhancing the company’s position in the healthcare market.

Bears say

BrightSpring Health's stock outlook is negatively influenced by the potential for reduced client budgets, which may adversely impact both the company's business and revenue generation. Furthermore, the reliance on prescription utilization and the potential decline in healthcare professionals prescribing certain therapies present additional risks that could negatively affect revenues and cash flows. Additionally, BrightSpring Health's substantial debt load may restrict its capacity for growth investments, further complicating its operational strategies amidst a competitive market landscape.

BTSG has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 9 analysts, BTSG has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.